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The effects of nine drugs on the CD spectra of a synthetic calcium binding analog of site III of rabbit 
skeletal troponin C, can generally be divided into 3 groups: (1) that consisting of haloperidol, benperidol, 
molindone and promethazine, had no effect on the CD spectrum or calcium sensitivity of the apopeptide; 
(2) that composed of structurally rigid thioxanthenes, induced CD-detectable structural change in the 
apopeptide but prevented Ca2+-induced structural change; (3) that consisting of chlo~romazine, trifluo- 
perazine and fluphenazine, induced structural change in the peptide but had no effect on the Ca’+-induced 
structural change. 
Circular dichrokm Drug binding 
1. INTRODUCTION 
Following the discovery of calmodulin (CaM), a 
small acidic protein capable of activating both 
CAMP dependent phosphodiester~e [ 1,211 and 
adenylate cyclase [3-71 in a calcium-dependent 
manner, Levin and Weiss demonstrated that anti- 
psychotic drugs inhibited the activation of CAMP 
phosphodiesterase [8]. Later, these same authors 
demonstrated that the phenothiazine antipsychotic 
trifluo~r~ne binds to c~mod~n and troponin 
C in the presence of calcium [9,10]. Although the 
pharmacological significance of such interactions 
with calmodulin remains a controversial topic 
[8-141, it is clear that these compounds share 
structural features (i.e., positively charged and 
Abbreviations: CaM, calmodulin; cAMP, 3 ‘-5 ’ cyclic 
adenosine monophosphate; CD, circular dichroism; 
EGTA, ethylene glycol bis @aminoethyl ether); 
N,iV,iV’,N’-tetraacetic acid; MOPS, 3-(N-morpholino) 
propanesulfonic acid; TnC, troponin C 
Synthetic peptide Troponin C 
hydrophobic domains) present on peptides and 
proteins known to interact with CaM and troponin 
C [15-211. Cyanogen bromide fragments contain- 
ing site III of bovine brain CaM [22] and site III 
of rabbit skeletal troponin C [23] have been shown 
to interact with phenothiazines. One of the drug 
binding sites was restricted to an 8 amino acid long 
region of troponin C (residues 95-102) found to be 
highly conserved in CaM (residues 85-92) [23]. We 
have synthesized a 34-residue analog of site III of 
rabbit skeletal troponin C (region 90- 123) contain- 
ing both the proposed trifluoper~ne-binding site 
and a high affinity calcium-binding region [24] and 
made use of this model peptide to examine the ef- 
fect of a variety of neuroleptic drugs on the secon- 
dary structure and the Ca*+-binding properties of 
this c~cium-binding unit. 
2. MATERIALS AND METHODS 
All chemicals and solvents are reagent grade 
unless otherwise stated. The drugs were generous 
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gifts from the following companies: 
trifluoperazine (Smith Kline and French, Mont- 
real, Quebec); cis- and trans-thiothixene (Pfizer 
Inc., Groton CT); benperidol, Janssen Phar- 
maceutica (Beerse); haloperidol, McNeil Labs 
(Stouffville, Ontario); molindone, Endo Labs 
(Garden City NY); chlorpromazine and pro- 
methazine, Poulenc Ltd. (Montreal, Quebec); 
fluphenazine, E.R. Squibb and Sons Ltd. (Mont- 
real, Quebec). 
2.1. Peptide synthesis and purification 
The 34-residue peptide was prepared by the 
automated solid-phase method, cleaved from the 
resin by anhydrous HF and purified by 
DEAE-Sephacel and hydroxyapatite 
chromatography as in [24]. 
2.2. Preparation of samples 
The buffer system chosen for the circular 
dichroism (CD) studies was 100 mM MOPS (pH 
6.0), 50 mM KCl, 5 mM EGTA. Ca*+ free buffers 
were prepared from deionized distilled water which 
had been treated with Chelex resin. The peptide 
was dissolved in the above buffer and dialyzed 
overnight against he same buffer to remove traces 
of calcium. The appropriate drug was dissolved in 
the above buffer, then the peptide and drug solu- 
tions were mixed to produce a drug : peptide ratio 
of 2.3 : 1 and the CD spectra were determined. The 
drug solutions were freshly prepared and maintain- 
ed in the dark throughout the circular dichroism 
experiments. To avoid contamination of solutions 
with Ca*+ from laboratory glassware, Nalgene 
beakers, test tubes and solution bottles were used 
throughout the study. Concentration of calcium 
solutions used in the study were determined by 
titration with a standard EGTA solution using 
murexide as an indicator [25]. Quantities of pep- 
tide were determined from either amino acid 
analysis or from measuring the absorbance of the 
peptide dissolved in 100 mM MOPS @H 6.0), 
50 mM KC1 and 5 mM EGTA using an 6275 of 
1.708 x lo3 M-‘.cm-’ determined using quan- 
titative amino acid analysis. 
2.3. Circular dichroism measurements 
CD measurements were made on a Cary 60 spec- 
tropolarimeter with a 6001 CD attachment as in 
[24]. The concentration of free Ca*’ in solution 
was controlled by an EGTA-containing buffer and 
calculated using the computer program in [26] as 
described in [24]. Calcium association constants 
were determined by a non-linear curve-fitting 
iterative procedure in [24]. 
3. RESULTS AND DISCUSSION 
A 34-amino acid residue peptide analog of 
calcium binding site III of troponin C and, by se- 
quence homology, site III of calmodulin (fig. 1) has 
been tested for interaction with representatives of 
4 different classes of neuroleptic drugs. The 
butyrophenones, represented by benperidol and 
haloperidol could not induce any CD-detectable 
structural change in the peptide up to a concentra- 
tion rate of 2.3 : 1, drug : peptide (fig.2). Earlier in- 
vestigations [11,211 had indicated that haloperidol 
did not bind to calmodulin as strongly as the 
phenothiazines. Thus the hydrophobic character 
of these drugs does not represent he sole criterion 
for a drug-peptide interaction. 
Both of the thioxanthenes, cis- and trans- 
thiothixene, induced a small amount of structure 
in the peptide and this class was the only class 
tested that prevented the peptide from responding 
normally to the addition of calcium; i.e., with an 
increase in CD-detectable structural change (fig.2). 
The possibility exists that the inflexibility of the 
sidechains linked to the tricyclic ring structure by 
a double bond may have some effect on the ability 
of the drug-peptide complex to bind calcium. 
A third class tested, the dihydroinolones, a non- 
classical group of neuroleptics represented by 
molindone [27], also failed to induce structural 
change in the peptide and did not affect the subse- 
quent structural change induced by addition of 
calcium (fig.2). Finally, the phenothiazines 
represented by promethazine, chlorpromazine, 
trifluoperazine and fluphenazine induced struc- 
tural change in the peptide in a manner correspon- 
ding to their in vitro ability to inhibit 
phosphodiesterase activation by calmodulin 
[11,21], but had no effect on the Ca*+-induced 
structural change (fig.2). Note that the calcium- 
binding constant of this model peptide is equal to 
2.6 x 10’ M-’ in the absence of drug [24]. Except 
for the case of the thioxanthene isomers, the bind- 
ing or presence of these drugs did not alter the 
calcium-binding property of the synthetic analog. 
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Fig. 1. Amino acid sequence of the calcium-binding sites in bovine brain calmodulin, rabbit skeletal troponin C and the 
synthetic 34-residue peptide. The calcium binding sites are numbered I-IV. Bovine brain calmodulin is the upper 
sequence while rabbit skeletal troponin C is the lower sequence. The 34-residue peptide, AcAgE STnC @C-123) amide, 
is indicated directly below rabbit skeletal troponin C site III and has an identical sequence to this site with the exceptions 
indicated. The sequences comprising the helix-loop-helix regions are indicated by bars at the top of the figure. The 
6 octahedral Ca2+ coor~nating positions are designated X, Y,Z, - Y, -X, - 2. The amino acid residues in the 
corresponding Ca” coordinating positions are circled. Amino acid residues are designated using the one-letter code. 
This observation is in agreement with proton an a-helical arrangement in the N-terminal region 
magnetic resonance and circular dichroism results of the peptide [23,24]. 
obtained for the binding of trifluoperazine to a Differences in ellipticity induced by 
cyanogen bromide fragment representing site III of phenothi~nes on the model peptide can be ra- 
rabbit skeletal troponin C 1231. tionalized in terms of the distance separating the 
In light of the interaction of calmodulin with a positively charged domain and the aromatic moie- 
variety of peptides, proteins [18,19,28,29] and tY Of the drug, as postulated in [21,23]. For in- 
structurally related antipsychotics [ 11,211, it was stance, the positive charge on trifluoperazine can 
concluded that all these structures share in com- be associated with either of the nitrogens of the 
mon an hydrophobic and a positively charged do- piperazine ring thus placing the charge at a 
main [20,21]. The analysis of the trifluoperazine- distance of 4 to 7 bondlengths from the aromatic 
binding site of site III of rabbit skeletal troponin C center. The same holds true for fluphenazine, but 
reveals that complementary hydrophobic and in the case of chlorpromazine and promethazine, 4 
negatively charged centers exist and are optimally and 3 bondlengths respectively separate the two 
positioned when calcium induces the formation of centers. 
- 
Fig.2. CD spectra: Drug and Ca2+ -induced CD spectra of the 34-residue peptide, native peptide ( --), peptide + drug 
(. . .), peptide + drug + ca2+ (---); peptide was 0.43 mM. The chemical structures of the various drugs are indicated 
beneath the corresponding spectrum. The Kca-values of the peptide in the presence of 1 mM drug are indicated at the 
top of the corresponding spectrum, The Kca-value of the peptide in the absence of any drug has been determined as 
2.6 x 10’ M-’ 1241. The CD spectrum for peptide + Ca2+ [24I is identical to that observed for peptide + Ca2+ + 
trifluoperazine. The experimental conditions are described in section 2; N.D., not determined. 
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In conclusion, this work has pointed out the 
selectivity of a 34-residue synthetic peptide 
representing site III of rabbit skeletal troponin C 
for a particular ciass of neuroleptics and indicated 
its potential use as a phenothiazine selective bind- 
ing region. 
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